The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: A randomized, placebo-controlled, double-blind, crossover studyCitation formats

  • Authors:
  • David Allen
  • Barbara McDonnell
  • Neil Wheeler
  • Raj K. Sharma
  • Andrew Sykes
  • And 1 others
  • External authors:
  • Ashley Woodcock

Standard

The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: A randomized, placebo-controlled, double-blind, crossover study. / Allen, David; McDonnell, Barbara; Wheeler, Neil; Sharma, Raj K.; Sykes, Andrew; Woodcock, Ashley.

In: Clinical Therapeutics, Vol. 27, No. 7, 07.2005, p. 1004-1012.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Allen, David ; McDonnell, Barbara ; Wheeler, Neil ; Sharma, Raj K. ; Sykes, Andrew ; Woodcock, Ashley. / The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: A randomized, placebo-controlled, double-blind, crossover study. In: Clinical Therapeutics. 2005 ; Vol. 27, No. 7. pp. 1004-1012.

Bibtex

@article{f8f2b407a7e5417d96c5eaf2333f7b9c,
title = "The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: A randomized, placebo-controlled, double-blind, crossover study",
abstract = "Objective: This study examined the clinical relevance of fine-particle mass (FPM) delivered from metered dose inhalers (MDIs) to bronchodilatation and bronchoprotection against methacholine challenge by comparing a marketed chlorofluorocarbon (CFC) formulation of salmeterol with an investigational hydrofluoroalkane (HFA) formulation. Methods: This was a randomized, double-blind, placebo-controlled, 3-way crossover study in patients with mild to moderate asthma who had a forced expiratory volume in 1 second (FEV 1) of",
keywords = "Asthma, Chlorofluorocarbon, Fine-particle mass, Hydrofluoroalkane, Methacholine challenge, Salmeterol",
author = "David Allen and Barbara McDonnell and Neil Wheeler and Sharma, {Raj K.} and Andrew Sykes and Ashley Woodcock",
year = "2005",
month = "7",
doi = "10.1016/j.clinthera.2005.07.006",
language = "English",
volume = "27",
pages = "1004--1012",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "7",

}

RIS

TY - JOUR

T1 - The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: A randomized, placebo-controlled, double-blind, crossover study

AU - Allen, David

AU - McDonnell, Barbara

AU - Wheeler, Neil

AU - Sharma, Raj K.

AU - Sykes, Andrew

AU - Woodcock, Ashley

PY - 2005/7

Y1 - 2005/7

N2 - Objective: This study examined the clinical relevance of fine-particle mass (FPM) delivered from metered dose inhalers (MDIs) to bronchodilatation and bronchoprotection against methacholine challenge by comparing a marketed chlorofluorocarbon (CFC) formulation of salmeterol with an investigational hydrofluoroalkane (HFA) formulation. Methods: This was a randomized, double-blind, placebo-controlled, 3-way crossover study in patients with mild to moderate asthma who had a forced expiratory volume in 1 second (FEV 1) of

AB - Objective: This study examined the clinical relevance of fine-particle mass (FPM) delivered from metered dose inhalers (MDIs) to bronchodilatation and bronchoprotection against methacholine challenge by comparing a marketed chlorofluorocarbon (CFC) formulation of salmeterol with an investigational hydrofluoroalkane (HFA) formulation. Methods: This was a randomized, double-blind, placebo-controlled, 3-way crossover study in patients with mild to moderate asthma who had a forced expiratory volume in 1 second (FEV 1) of

KW - Asthma

KW - Chlorofluorocarbon

KW - Fine-particle mass

KW - Hydrofluoroalkane

KW - Methacholine challenge

KW - Salmeterol

U2 - 10.1016/j.clinthera.2005.07.006

DO - 10.1016/j.clinthera.2005.07.006

M3 - Article

VL - 27

SP - 1004

EP - 1012

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 7

ER -